A case report of an 18-year-old receiving nebulized lidocaine for treatment of COVID-19 cough

Nebulised lidocaine was previously used in infants and children undergoing flexible bronchoscopy and was safe and beneficial. The aim of this randomised controlled trial was to assess the impact of preoperative nebulised lidocaine on the incidence of perioperative respiratory adverse events in children aged one to five years proposed for ilioinguinal ambulatory surgery while having mild symptoms of upper respiratory tract infection. Patients were randomly allocated to one of the two groups of the study: Group L (lidocaine) received 4 mg/kg of nebulised lidocaine 2% (0.2 ml/kg), and Group P (placebo) received 0.2 ml/kg of normal saline nebulisation, 30 minutes before anaesthesia. Nebulised lidocaine reduced the risk of bronchospasm, with p = 0.003 and a risk ratio (RR) = 0.326 [0.140–0.760], and prolonged oxygen support postoperatively, with p = 0.004 and RR = 0.222 [0.067–0.732]. It also reduced the risk of hospitalisation, with p = 0.001 and RR = 0.138 [0.033–0.577]. No side effects for nebulised lidocaine 2% were noted. Preoperative nebulised lidocaine seems to be a safe and efficient premedication for children with upper respiratory tract infections.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A case report of an 18-year-old receiving nebulized lidocaine for treatment of COVID-19 cough

Cited by 5 publications

References 30 publications

Multiple drugs

Multiple drugs

Systems medicine framework for repurposable drug combinations for COVID-19 comorbidities

Preoperative nebulised lidocaine for children with mild symptoms of upper respiratory tract infections: A randomised controlled trial

Contact Info

Product

Resources

About